

Table 3. Additional Virucidal effectiveness studies performed *in vitro* and *in vivo**

Challenge viruses tested <i>in vitro</i> by ASTM E 1052 suspension		Reduction in 15 seconds	
		Log₁₀	%
1	Hepatitis A virus	≥10 ⁶	≥99.9992
2	Duck hepatitis B virus [surrogate for hepatitis B virus (HBV)]	≥ 3.2	≥ 99.94
3	Bovine viral diarrhea virus (surrogate for hepatitis C virus (HCV)]	≥10 ^{8.1}	≥99.999992
4	Herpes simplex virus type 1 (HSV-1)	≥10 ^{6.6}	≥ 99.999997
5	Herpes simplex virus type 2 (HSV-2)	≥10 ^{6.85}	≥ 99.99998
6	Human coronavirus 229E	≥10 ^{4.1}	≥ 99.992
7	SARS -Human coronavirus	≥10 ^{4.85}	≥ 99.998
8	Human immunodeficiency virus	≥10 ⁶	≥ 99.9992
9	Respiratory syncytial virus	≥ 10 ^{6.35}	≥ 99.99995
10	Vaccinia virus	≥ 7.0	≥ 99.99999
Challenge viruses tested <i>in vivo</i> by ASTM E 1838 Fingerpad method		Reduction in ≤ 30 seconds	
1	Human Adenovirus type 5 (VR-5)	3.27	99.92
2	Influenza A virus	3.92	99.98
3	Feline calicivirus (surrogate for Noroviruses)	2.69	99.31
4	Rhinovirus	3.19	99.91
5	Rotavirus	3.33	99.94

*Data on file.